Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) and Idera Pharmaceuticals Inc. (NASDAQ:IDRA) compete against each other in the Biotechnology sector. We will contrast them and contrast their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Kiniksa Pharmaceuticals Ltd.||N/A||0.00||153.07M||-1.92||0.00|
|Idera Pharmaceuticals Inc.||N/A||218.94||50.76M||-2.48||0.00|
Table 1 shows the top-line revenue, earnings per share and valuation for Kiniksa Pharmaceuticals Ltd. and Idera Pharmaceuticals Inc.
Table 2 shows us the return on equity, return on assets and net margins of both businesses.
|Net Margins||Return on Equity||Return on Assets|
|Kiniksa Pharmaceuticals Ltd.||0.00%||0%||0%|
|Idera Pharmaceuticals Inc.||0.00%||-68.4%||-60.4%|
12.2 and 12.2 are the respective Current Ratio and a Quick Ratio of Kiniksa Pharmaceuticals Ltd. Its rival Idera Pharmaceuticals Inc.’s Current and Quick Ratios are 8.2 and 8.2 respectively. Kiniksa Pharmaceuticals Ltd. has a better chance of clearing its pay short and long-term debts than Idera Pharmaceuticals Inc.
The table delivered features the ratings and recommendations for Kiniksa Pharmaceuticals Ltd. and Idera Pharmaceuticals Inc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Kiniksa Pharmaceuticals Ltd.||0||0||1||3.00|
|Idera Pharmaceuticals Inc.||0||0||2||3.00|
Kiniksa Pharmaceuticals Ltd.’s upside potential is 72.30% at a $26 consensus target price. Meanwhile, Idera Pharmaceuticals Inc.’s consensus target price is $10.5, while its potential upside is 230.19%. The data provided earlier shows that Idera Pharmaceuticals Inc. appears more favorable than Kiniksa Pharmaceuticals Ltd., based on analyst view.
Insider & Institutional Ownership
Institutional investors owned 74.8% of Kiniksa Pharmaceuticals Ltd. shares and 46.5% of Idera Pharmaceuticals Inc. shares. Insiders owned roughly 12.97% of Kiniksa Pharmaceuticals Ltd.’s shares. Competitively, insiders own roughly 0.7% of Idera Pharmaceuticals Inc.’s shares.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Kiniksa Pharmaceuticals Ltd.||1.59%||2.4%||-12.37%||-16.65%||0%||-36.21%|
|Idera Pharmaceuticals Inc.||-2.74%||12.25%||-55.9%||-71.46%||-80.06%||2.53%|
For the past year Kiniksa Pharmaceuticals Ltd. has -36.21% weaker performance while Idera Pharmaceuticals Inc. has 2.53% stronger performance.
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. It uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense (3GA) technology. The companyÂ’s drug candidates include IMO-2125, an agonist that is in Phase I/II clinical trials in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma and refractory solid tumors; IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis. It also develops IDRA-008 for undisclosed liver target for rare disorder; 3GA compound for renal target; and IMO-9200, a drug candidate for potential use in selected autoimmune disease indications. In addition, the company is developing drug candidates to turn off the messenger RNA associated with disease causing genes. Idera Pharmaceuticals, Inc. has collaboration and license agreement with GSK to research, develop, and commercialize selected molecules from its 3GA technology for the treatment of selected targets in renal disease; collaboration with Abbott Molecular Inc. for the development of an in vitro companion diagnostic; and Merck & Co to research, develop, and commercialize vaccine products. The company was founded in 1989 and is based in Cambridge, Massachusetts.